Accounts filed on 31-12-2015
Accounts filed on 31-12-2015
trueSQR PHARMA CONSULTING LTD089016892015-12-31671086419786672086420786100010006720864207866207810129286742078671771-117626114615418097511217925169212597163412190042462914731211221096538412413820691216958536343Basis of accounting
The financial statements have been prepared under the historical cost convention, and in accordance with the Financial Reporting Standard for Smaller Entities (effective January 2015).
Turnover
The turnover shown in the profit and loss account represents amounts invoiced during the year, exclusive of Value Added Tax.
Intangible Assets
Intangible assets acquired separately from a business are capitalised at cost. Intangible assets
acquired as part of an acquisition of a business are capitalised separately from goodwill if the fair
value can be measured reliably on initial recognition, subject to the constraint that, unless the asset
has a readily ascertainable market value, the fair value is limited to an amount that does not create or
increase any negative goodwill arising on the acquisition. Intangible assets, excluding development costs,
created within the business are not capitalised and expenditure is charged against profits in the year in
which it is incurred.
Intangible assets are amortised on a straight line basis over their estimated useful lives up to a maximum
of 20 years. The carrying value of intangible assets is reviewed for impairment at the end of the first full
year following acquisition and in other periods if events or changes in circumstances indicate the carrying
value may not be recoverable.
Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of the transaction. Exchange differences are taken into account in arriving at the operating profit.
41382069206912169585363436806151221096538412682684Ordinary1000110001000Ordinary11000100010002016-09-28MR. FERDINANDO FUSAROtruetruetruetruexbrli:sharesiso4217:GBPxbrli:pureSQR PHARMA CONSULTING LTD2015-01-012015-12-31SQR PHARMA CONSULTING LTD2014-02-192014-12-31SQR PHARMA CONSULTING LTD2014-02-18SQR PHARMA CONSULTING LTD2014-12-31SQR PHARMA CONSULTING LTD2014-12-31SQR PHARMA CONSULTING LTD2015-12-31 2016-09-29
